Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
701-720 of 1,782 trials

Kidney Function: Vonafexor Study

We are studying the effects of vonafexor on kidney function in people with impaired renal function and suspected MASH. The trial will help us understand how different doses impact kidney health and safety.

Impaired Renal Function and Suspected MASH6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Thyroid Eye Disease: Efgartigimod PH20 SC

We are studying a new treatment for adults with thyroid eye disease to see if it reduces eye bulging compared to a placebo. This trial will help us understand its effectiveness and safety.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

Thyroid Eye Disease: Efgartigimod PH20 SC Study

We are testing a new treatment called efgartigimod PH20 SC in adults with thyroid eye disease. The goal is to see if it works better than a placebo in reducing symptoms.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

BRAF-V600E Mutant Metastatic Colorectal Cancer: BRAVE Trial

We are studying a combination of encorafenib, cetuximab, and bevacizumab for patients with BRAF-V600E mutated metastatic colorectal cancer who have not responded to previous treatments. The trial aims to evaluate the safety and effectiveness of this treatment approach.

Metastatic Colorectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Fast-Acting Insulins and Their Post-Meal Effects in Type 1 Diabetes

We are studying how different fast-acting insulins affect blood sugar levels after meals in people with type 1 diabetes. This research may help identify the best insulin for managing glucose and reducing oxidative stress.

Type 1 Diabetes1-2 yearsSafety phase (I)No PlaceboStandard MedicinesDiabetologyEndocrinology

Cytisine vs. Nicotine Replacement Therapy for Smokers with Chronic Kidney Disease

We are studying whether cytisine can help nicotine-dependent patients with chronic kidney disease quit smoking more effectively than traditional nicotine replacement therapy. This trial will also look at any side effects from both treatments.

Nicotine DependenceChronic Kidney DiseaseMonitoring phase (IV)No PlaceboStandard MedicinesNephrologyPsychiatry

MOG Antibody-Associated Disease: Rozanolixizumab Study

We are studying whether Rozanolixizumab is effective and safe for adults with MOG antibody-associated disease. This research aims to provide insights into a potential new treatment for this condition.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurology

Ulcerative Colitis in Kids: Ozanimod Study

We are testing the oral medication ozanimod in children with moderately to severely active ulcerative colitis who haven't responded to other treatments. The goal is to see if it helps improve their symptoms and overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Melanoma Treatment: Nivolumab with Isolated Limb Perfusion

We are studying whether combining nivolumab with isolated limb perfusion helps patients with in-transit melanoma metastases achieve better treatment responses. This trial will also look at safety and quality of life.

In-transit Metastasis of Malignant Melanoma1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteDermatologyOncology

Heart Attack Treatment: EVOLocumab Study

We are studying whether adding evolocumab to standard cholesterol management helps reduce serious heart-related events in patients recently hospitalized for a heart attack. This trial aims to improve outcomes for those affected by acute myocardial infarction.

High Cholesterol>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

ColiFin® Therapy for Adults with Bronchiectasis and Pseudomonas Infection

We are studying whether inhaled ColiFin® can improve health in adults with bronchiectasis who have a new asymptomatic Pseudomonas aeruginosa infection. The trial compares this treatment to standard care to see which is more effective.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Lobular Breast Cancer: Capivasertib and Fulvestrant Study

We are studying a new treatment combination for patients with high-risk lobular breast cancer to see if it improves cancer control and safety compared to standard therapy.

Invasive Lobular Breast Carcinoma≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Complement 3 Glomerulopathy: Study of Iptacopan

We are evaluating the safety and effectiveness of iptacopan for patients with complement 3 glomerulopathy. The study aims to see if it can reduce protein levels in urine and improve kidney function.

C3 Glomerulopathy1-2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNephrology

C3 Glomerulopathy: Iptacopan Study

We are studying the long-term safety and effectiveness of iptacopan for individuals with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis. This research aims to understand how well the treatment works in improving kidney health.

C3 Glomerulopathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Radial Nerve Block: Opioid Tolerant Individuals

We are studying how long a radial nerve block lasts in people who are tolerant to opioids versus those who are not. This may help improve pain management for patients with opioid use.

Postoperative PainMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology

Systemic Sclerosis-Related Lung Disease: Belimumab Study

We are investigating the long-term safety and effects of belimumab in adults with lung disease linked to systemic sclerosis. This study aims to see how the treatment impacts lung function and overall tolerability.

Lung Involvement in Systemic SclerosisBronchial Diseases>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPulmonologyRheumatology

Crohn's Disease: Vedolizumab with Upadacitinib

We are studying whether a combination of vedolizumab and upadacitinib helps improve symptoms in adults with moderately to severely active Crohn's disease compared to vedolizumab alone.

Crohn's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Cardiovascular Disease: Gene Analysis for Statin Treatment

We are studying whether a gene analysis strategy can help people at risk of cardiovascular disease better tolerate statins and reduce side effects. This trial compares this approach to standard treatment methods.

Patients at Risk of Cardiovascular Disease6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Dilated Cardiomyopathy: Risedronate Treatment

We are studying whether Risedronate can improve heart function in patients with dilated cardiomyopathy caused by a Troponin T gene mutation. We also want to assess its safety and impact on physical performance.

Dilated Cardiomyopathy1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Preventing Opioid-Induced Constipation in Advanced Cancer Patients

We are comparing two laxatives to see which one better prevents constipation in patients with advanced cancer starting opioid pain treatment. This study will also assess quality of life and side effects.

Advanced Cancer≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOncology